GUD:CC News and Press, Knight Therapeutics Inc. From 03/21/24

Bridgemarq Real Estate Services Inc. Restricted Voting Shares (BRE:CA) is expected to report for quarter end 2023-12-31 Avivagen Inc. (VIV:CA) is expected to report for quarter end 2024-01-31 Andean Precious Metals Corp. (APM:CA) is expected to report $0 for Q4 2023 Aimia Inc. (AIM:CA...

MONTREAL, March 14, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end 2023 financial results on Thursday, March 21, 2024 prior to market opening. Fol...

2024-02-29 16:50:00 ET The last few years saw a surge in healthcare companies entering the market. The pandemic led to many opportunities and many failures. So, where can investors go to invest in what really should be a stable area of investment? After all, we’re always going to...

MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of Minjuvi ® (tafasitamab) by its Brazilian affiliate, United Medical Ltda. Minjuvi ® is indicated in...

MONTREAL, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it is marking its 10-year anniversary, and celebrating a decade of expansion and growth. Since its inception on February...

MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Brazilian affiliate, United Medical Ltda., has submitted a marketing authorization application to ANVISA, the Brazilian he...

MONTREAL, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a Pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of BIJUVA ® (estradiol and progesterone) capsules in Canada. BIJUVA ® is indicated for the treatment ...

MONTREAL, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive license agreement with Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal"), granting Knigh...

2024-01-23 16:10:00 ET Growth stocks had a respectable showing in 2023 amid rising interest rates. The tech sector, in particular, carried the TSX for most of the year. However, it’s back to zero in 2024. Since growth investing is still the theme, some stocks outside the tech sec...

MONTREAL, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today the launch of IMVEXXY ® in Canada. IMVEXXY ® (estradiol vaginal inserts) is approved for the treatment of postme...